Biocon
Abulkalam Aasath is an experienced professional in the chemical engineering field, currently serving as an Executive at Biocon since January 2022. Additionally, Abulkalam leads a team at Bhumi from February 2020 to the present. Prior experience includes a role as a Chemist at Jubilant Generics Limited from October 2021 to January 2022. Abulkalam holds a Bachelor of Technology in Chemical Engineering from Sri Venkateswara College of Engineering, completed in 2021, as well as a Diploma in Chemical Engineering from The Kongu Polytechnic College, attained in 2015.
This person is not in any teams
This person is not in any offices
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.